vs
Side-by-side financial comparison of Huntington Ingalls Industries (HII) and Zoetis (ZTS). Click either name above to swap in a different company.
Huntington Ingalls Industries is the larger business by last-quarter revenue ($3.5B vs $2.4B, roughly 1.5× Zoetis). Zoetis runs the higher net margin — 25.3% vs 4.6%, a 20.7% gap on every dollar of revenue. On growth, Huntington Ingalls Industries posted the faster year-over-year revenue change (15.7% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $516.0M). Over the past eight quarters, Huntington Ingalls Industries's revenue compounded faster (11.3% CAGR vs 4.4%).
Huntington Ingalls Industries, Inc. (HII) is the largest military shipbuilding company in the United States as well as a provider of professional services to partners in government and industry. HII was formed on 31 March 2011, as a divestiture from Northrop Grumman.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
HII vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.5B | $2.4B |
| Net Profit | $159.0M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 4.9% | 31.9% |
| Net Margin | 4.6% | 25.3% |
| Revenue YoY | 15.7% | 3.0% |
| Net Profit YoY | 29.3% | 3.8% |
| EPS (diluted) | $4.06 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.5B | $2.4B | ||
| Q3 25 | $3.2B | $2.4B | ||
| Q2 25 | $3.1B | $2.5B | ||
| Q1 25 | $2.7B | $2.2B | ||
| Q4 24 | $3.0B | $2.3B | ||
| Q3 24 | $2.7B | $2.4B | ||
| Q2 24 | $3.0B | $2.4B | ||
| Q1 24 | $2.8B | $2.2B |
| Q4 25 | $159.0M | $603.0M | ||
| Q3 25 | $145.0M | $721.0M | ||
| Q2 25 | $152.0M | $718.0M | ||
| Q1 25 | $149.0M | $631.0M | ||
| Q4 24 | $123.0M | $581.0M | ||
| Q3 24 | $101.0M | $682.0M | ||
| Q2 24 | $173.0M | $624.0M | ||
| Q1 24 | $153.0M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | 4.9% | 31.9% | ||
| Q3 25 | 5.0% | 37.0% | ||
| Q2 25 | 5.3% | 36.7% | ||
| Q1 25 | 5.9% | 36.5% | ||
| Q4 24 | 3.7% | 31.6% | ||
| Q3 24 | 3.0% | 36.6% | ||
| Q2 24 | 6.3% | 33.0% | ||
| Q1 24 | 5.5% | 34.1% |
| Q4 25 | 4.6% | 25.3% | ||
| Q3 25 | 4.5% | 30.0% | ||
| Q2 25 | 4.9% | 29.2% | ||
| Q1 25 | 5.4% | 28.4% | ||
| Q4 24 | 4.1% | 25.1% | ||
| Q3 24 | 3.7% | 28.6% | ||
| Q2 24 | 5.8% | 26.4% | ||
| Q1 24 | 5.5% | 27.4% |
| Q4 25 | $4.06 | $1.37 | ||
| Q3 25 | $3.68 | $1.63 | ||
| Q2 25 | $3.86 | $1.61 | ||
| Q1 25 | $3.79 | $1.41 | ||
| Q4 24 | $3.15 | $1.29 | ||
| Q3 24 | $2.56 | $1.50 | ||
| Q2 24 | $4.38 | $1.37 | ||
| Q1 24 | $3.87 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $2.7B | — |
| Stockholders' EquityBook value | $5.1B | $3.3B |
| Total Assets | $12.7B | $15.5B |
| Debt / EquityLower = less leverage | 0.53× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | $10.0M | $2.0B |
| Q4 25 | $2.7B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.7B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $5.1B | $3.3B | ||
| Q3 25 | $5.0B | $5.4B | ||
| Q2 25 | $4.9B | $5.0B | ||
| Q1 25 | $4.8B | $4.7B | ||
| Q4 24 | $4.7B | $4.8B | ||
| Q3 24 | $4.2B | $5.2B | ||
| Q2 24 | $4.2B | $5.0B | ||
| Q1 24 | $4.1B | $5.1B |
| Q4 25 | $12.7B | $15.5B | ||
| Q3 25 | $12.3B | $15.2B | ||
| Q2 25 | $12.1B | $14.5B | ||
| Q1 25 | $12.1B | $14.1B | ||
| Q4 24 | $12.1B | $14.2B | ||
| Q3 24 | $11.1B | $14.4B | ||
| Q2 24 | $11.3B | $14.2B | ||
| Q1 24 | $11.2B | $14.3B |
| Q4 25 | 0.53× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.58× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $650.0M | $893.0M |
| Free Cash FlowOCF − Capex | $516.0M | $732.0M |
| FCF MarginFCF / Revenue | 14.8% | 30.7% |
| Capex IntensityCapex / Revenue | 3.9% | 6.7% |
| Cash ConversionOCF / Net Profit | 4.09× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $794.0M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $650.0M | $893.0M | ||
| Q3 25 | $118.0M | $938.0M | ||
| Q2 25 | $823.0M | $486.0M | ||
| Q1 25 | $-395.0M | $587.0M | ||
| Q4 24 | $391.0M | $905.0M | ||
| Q3 24 | $213.0M | $951.0M | ||
| Q2 24 | $-9.0M | $502.0M | ||
| Q1 24 | $-202.0M | $595.0M |
| Q4 25 | $516.0M | $732.0M | ||
| Q3 25 | $13.0M | $805.0M | ||
| Q2 25 | $727.0M | $308.0M | ||
| Q1 25 | $-462.0M | $438.0M | ||
| Q4 24 | $277.0M | $689.0M | ||
| Q3 24 | $125.0M | $784.0M | ||
| Q2 24 | $-99.0M | $370.0M | ||
| Q1 24 | $-277.0M | $455.0M |
| Q4 25 | 14.8% | 30.7% | ||
| Q3 25 | 0.4% | 33.5% | ||
| Q2 25 | 23.6% | 12.5% | ||
| Q1 25 | -16.9% | 19.7% | ||
| Q4 24 | 9.2% | 29.7% | ||
| Q3 24 | 4.5% | 32.8% | ||
| Q2 24 | -3.3% | 15.7% | ||
| Q1 24 | -9.9% | 20.8% |
| Q4 25 | 3.9% | 6.7% | ||
| Q3 25 | 3.3% | 5.5% | ||
| Q2 25 | 3.1% | 7.2% | ||
| Q1 25 | 2.5% | 6.7% | ||
| Q4 24 | 3.8% | 9.3% | ||
| Q3 24 | 3.2% | 7.0% | ||
| Q2 24 | 3.0% | 5.6% | ||
| Q1 24 | 2.7% | 6.4% |
| Q4 25 | 4.09× | 1.48× | ||
| Q3 25 | 0.81× | 1.30× | ||
| Q2 25 | 5.41× | 0.68× | ||
| Q1 25 | -2.65× | 0.93× | ||
| Q4 24 | 3.18× | 1.56× | ||
| Q3 24 | 2.11× | 1.39× | ||
| Q2 24 | -0.05× | 0.80× | ||
| Q1 24 | -1.32× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HII
| Aircraftcarriers | $984.0M | 28% |
| Fixedpriceincentive | $758.0M | 22% |
| Submarines | $744.0M | 21% |
| Surfacecombatantsandcoastguardcutters | $452.0M | 13% |
| Amphibiousassaultships | $433.0M | 12% |
| Costtype | $123.0M | 4% |
| Otherprograms | $4.0M | 0% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
